Rifampicin and colistin in the treatment of infections from multiresistant acinetobacter baumannii

Nosocomial infections by Acinetobacter baumannii are responsible for an increase in mortality and the duration of hospitalization. Imipenem represented during main years the 'Gold standard' in the treatment of infections due to Acinetobacter baumannii, however the emergence of resistances to this molecule in many hospitals constitutes a significant therapeutic challenge. The good sensitivity of this germ invitro to colistine, increased by the association of rifampicine supported the intravenous use of these antibiotics in vivo. We report our experience with rifampicine-colistine association for the treatment of infections due to Acinetobacter baumannii multiresistant in the surgical resuscitation unit of the CHU Sahloul of Sousse